- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying ...

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. New ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...